DBV TECHNOLOGIES 
DelveInsight's, "Peanut Allergy Pipeline Insight, 2022," report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Peanut Allergy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key takeaways from the Peanut Allergy Pipeline Report *DelveInsight's Peanut Allergy Pipeline report depicts a robust space with 15+ active players working to develop 15+ pipeline therapies for Peanut Allergy. *The leading Peanut Allergy Companies are working such as
Recent Developmental Activities in the Peanut Allergy Pipeline *DBV is developing the Viaskin technology platform, which delivers biologically active compounds, including allergens, via intact skin. Viaskin is an electrostatic patch, based on Epicutaneous Immunotherapy, or EPIT®, which administers an allergen directly onto the superficial layers of the skin to activate the immune system by specifically targeting antigen-presenting cells without allowing passage of the antigen into the bloodstream. It is currently in preregistration stage of development. *Dupilumab is a IL-4R Antibody that is being developed by
Request a sample and discover the recent advances in Peanut Allergy Treatment Drugs @ Peanut Allergy Pipeline Outlook Report
Peanut Allergy Overview
A peanut allergy is a reaction that occurs when your body mistakenly identifies peanuts as harmful substances. When you eat peanuts or food containing peanuts, your immune system -the body's natural defense system that fights infections and diseases-overreacts and can cause a serious, even life-threatening response. Symptoms of peanut allergy can range from mild to severe. If you have a mild reaction, you may get a stomachache, a runny nose, itchy eyes, hives, or tingling in your lips or tongue. Your symptoms may start from within a few minutes to a few hours after eating peanuts or peanut products.
Peanut Allergy Emerging Drugs Profile *Viaskin Peanut:
Peanut Allergy Pipeline Therapeutics Assessment
There are approx. 15+ key companies which are developing the therapies for Peanut Allergy. The companies which have their Peanut Allergy drug candidates in the most advanced stage, i.e. preregistration include,
Get an overview of the Peanut Allergy Pipeline Report @ Peanut Allergy Ongoing Clinical Trials Analysis
Scope of the Peanut Allergy Pipeline Report *Coverage- Global *Peanut Allergy Companies are working such as
Table of Content *Introduction *Peanut Allergy Executive Summary *Peanut Allergy: Overview *Peanut Allergy Pipeline Therapeutics *Peanut Allergy Therapeutic Assessment *Late Stage Products (Preregistration) *Viaskin Peanut:
Key Questions
Current Treatment Scenario and Emerging Therapies: *How many companies are developing Peanut Allergy drugs? *How many Peanut Allergy drugs are developed by each company? *How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Peanut Allergy? *What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Peanut Allergy therapeutics? *What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? *What are the clinical studies going on for Peanut Allergy and their status? *What are the key designations that have been granted to the emerging drugs?
For further information on the Peanut Allergy Pipeline therapeutics, reach out to Peanut Allergy Treatment Landscape
Media Contact
Company
Contact Person:
Email: ybhardwaj@delveinsight.com
Phone: 09193216187
Address:
City:
State:
Country:
Website: https://www.delveinsight.com/
Source: www.abnewswire.com
.
(C) 2022 M2 COMMUNICATIONS, source
